跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

Niraparib Tosylate

Niraparib Tosylate API

Niraparib Tosylate-API

CAS Number: 1613220-15-7

治疗类别
抗癌/抗肿瘤
API技术
合成
剂型
Oral Solid/Tablets
瑞迪博士研发状态
正在开发中
创新品牌(美国)
Verzenio
Plant
EMQA

作用机制

Niraparib works by blocking the activity of PARP enzymes, which leads to the accumulation of DNA damage and ultimately cell death in cancer cells. This mechanism of action is thought to be particularly effective in cancer cells that have deficiencies in homologous recombination DNA repair, such as those with mutations in the BRCA1 or BRCA2 genes.

Niraparib is indicated for the treatment of ovarian cancer, specifically in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The medication is used as a maintenance treatment and is taken orally in tablet form.

适应症

Niraparib (brand name Zejula) is a medication that is indicated for the treatment of ovarian cancer. Specifically, it is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapeutic regimens and who have a deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) tumor.

Niraparib is a poly ADP ribose polymerase (PARP) inhibitor, which works by blocking the activity of PARP enzymes in cancer cells. This leads to the accumulation of DNA damage and ultimately cell death in cancer cells. The mechanism of action is thought to be particularly effective in cancer cells that have deficiencies in homologous recombination DNA repair, such as those with mutations in the BRCA1 or BRCA2 genes.

Niraparib is taken orally in tablet form and is used as a maintenance treatment, meaning it is taken after initial treatment with chemotherapy to help prevent the cancer from returning. The medication is used in combination with other treatments, as determined by a healthcare provider.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 Niraparib Tosylate API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

Oncology API Products:

Learn More

联系我们

请填写以下表格,我们会尽快与您联系

给我们发电子邮件: api@drreddys.com | +91 40 49002222

如果您有任何特定于国家的要求,我们将为您提供帮助。

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。